Annovis Bio, Inc. (ANVS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
	10-K	10-K	10-K	10-K	10-K	S-1/A
Operating expenses:
Research and development	16.5	8.5	3.1	0.8
General and administrative	9.0	6.1	3.6	0.8	0.6	0.4
Total operating expenses	25.5	14.5	6.6	1.6	0.7	0.4
Operating loss	-25.5	-14.5	-6.6	-1.6	-0.7	-0.7

Other income:
Interest income, net	0.2	0.0	0.0	0.0	0.0	0.0
Total other income	0.2	0.1	1.2	0.6
Loss before income taxes	-25.3	-14.5	-5.5	-1.0
Net loss	-25.3	-14.5	-5.5	-1.0	-0.7	-0.7

Basic loss per common share	($3.10)	($1.90)	($0.87)	($3.51)	($2.57)	($2.66)
Diluted loss per common share	($3.10)	($1.90)	($0.87)	($3.51)	($2.57)	($2.66)

Weighted average number of common shares outstanding, basic	8.2	7.6	6.3	0.3	0.3	0.3
Weighted average number of common shares outstanding, diluted	8.2	7.6	6.3